Form 4: Agios Pharmaceuticals CEO Brian Goff Executes Stock Transactions Following PSU Vesting

CEO Brian Goff of Agios Pharmaceuticals sold shares to cover tax obligations after performance share units vested, while also acquiring shares through the vesting of these units.

Summary

• On June 5, 2024, Brian Goff, CEO of Agios Pharmaceuticals, engaged in transactions involving the company's common stock.
• Goff acquired 25,527 shares through the vesting of performance share units (PSUs) at a price of $0.
• Simultaneously, he sold 12,115 shares at $48.84 per share to cover tax withholding obligations related to the PSU vesting.
• Following these transactions, Goff directly owns 67,192 shares of Agios Pharmaceuticals common stock and 76,583 performance share units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to compensation. The vesting of PSUs is a positive sign, but the sale of shares is a standard practice for tax purposes.

Positives

• The vesting of performance share units indicates the achievement of certain clinical milestones, which is a positive sign for the company's progress.
• The sale of shares to cover tax obligations is a routine transaction and does not necessarily indicate a negative outlook from the CEO.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of PSUs suggests continued progress towards achieving clinical and regulatory milestones.

Industry Context

Executive stock transactions are common and often related to compensation and tax planning. The vesting of performance share units is tied to company performance, reflecting alignment between management incentives and shareholder value.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of the company achieving its milestones.
• Employees may be motivated by the achievement of milestones that trigger PSU vesting.

Key Dates